Here, we discuss how tumor intrinsic oncogenic factors subvert desirable intratumoral inflammation by suppressing immunogenic cell death.doi:10.1080/2162402X.2021.1893466Samuel T WorkenheJonathan PolGuido Kroemer
Here, we reveal that tumor-intrinsic YTHDF1 drives immune evasion and immune checkpoint inhibitor (ICI) resistance. Additionally, YTHDF1 deficiency converts cold tumors into responsive hot tumors, which improves ICI efficacy. Mechanistically, YTHDF1 deficiency inhibits the translation of lysosomal ...
30,31,32. This is likely facilitated in CD4+CAR T cells that do not require major histocompatibility complex (MHC) class II expression on tumor cells for contact-dependent cytotoxic activity (as compared to conventional CD4+T cells). Furthermore, the production of cytokines such as IFN-γ and...
Particularly, we found that CD8[+] T lymphocytes abundantly expressed CXCR3, a receptor of CXCL10, by flow cytometry, indicating that tumor-intrinsic CXCL10 potentially recruited CD8[+] T in tumor microenvironment. ...
In this review, we will describe the mechanisms by which tumor-intrinsic signaling pathways regulate the immunosuppressive tumor microenvironment, including the decrease in effective immunocyte infiltration and function and the accumulation of immunosuppressive cells in the tumor microenvironment, which may ...
This study aimed to investigate whether tumor-intrinsic IFNα and CXCL10 determine the recruitment and activation of CD8+ T cells to become "hot tumor." In this study, we found that CXCL10 overexpressed in a variety of tumors including lung, colon, and liver tumors with a correlation with ...
Mechanistically, cancer cell-intrinsic IRE1α activation sustains mPGES-1 expression, enabling production of the immunosuppressive lipid mediator prostaglandin E. Accordingly, restoring mPGES-1 expression in IRE1αcancer cells rescues normal tumor progression. We have developed an IRE1α gene signature ...
另外,2018年5月14日,澳大利亚昆士兰大学Mark J Smyth团队在Journal of Clinical Investigation(IF=16) 在线发表题为“CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms”的研究论文,该研究发现PD-1 或 PD-1 和 CTLA4 的阻断在 CD155 受限的环境中更有效,这表明共同靶向 PD...
Blinatumomab, a bispecific antibody that directs CD3+ T cells to CD19+ tumor cells, shows variable efficacy in B-progenitor acute lymphoblastic leukemia (B-ALL). To determine tumor-intrinsic and -extrinsic determinants of response, we studied 44 adults with relapsed or refractory B-ALL (including...
However, to date, only a restricted portion of patients benefit from these therapies, due to natural and acquired resistance relying on the ever-evolving cross-talk between tumor and stromal cells. Here, we review the convergence of tumor-intrinsic and -extrinsic cues, both affecting tumor ...